Full Press Release Details
Pharmaceuticals announces that Dr. Michael Berelowitz, Senior Vice
at Pfizer, Joins its Board of Directors
Israel, May 18, 2010-- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced
that Dr. Michael Berelowitz, MD, joins Oramed Pharmaceuticals' Board of
Directors. Dr. Berelowitz is currently Senior Vice President and Head of
Clinical Development and Medical Affairs in the Specialty Care Business Unit at
Pfizer, Inc., the world's largest research-based pharmaceutical
Berelowitz joined Pfizer in 1996, after a number of years in academia, as a
Medical Director in the Diabetes Clinical Research team. Since then he has
assumed positions of increasing responsibility until being appointed to his
present role in 2009. Among his public activities, Dr. Berelowitz has served on
the board of directors of the American Diabetes Association, the Clinical
Initiatives Committee of the Endocrine Society, and has chaired the Task Force
on Research of the New York State Council on Diabetes. He has also served on
several editorial boards, including the Journal of Clinical Endocrinology and
Metabolism and Endocrinology, Reviews in Endocrine and Metabolic Disorders and
Clinical Diabetes. Dr. Berelowitz has authored and co-authored more than 100
peer-reviewed journal articles and book chapters in the areas of pituitary
growth hormone regulation, diabetes and metabolic disorders.
Michael Berelowitz joins our board and Oramed gains a renowned industry leader
in the study of diabetes. His extensive experience should help us bring our
insulin capsule ORMD-0801 through trials and to market. We are delighted to have
him as part of our team," states Nadav Kidron, Oramed Chief Executive
been closely following Oramed's progress and am impressed with the
significant advances that the company has made in developing its novel oral
insulin capsule, ORMD-0801," said Dr. Berelowitz. "I am very pleased to join
Oramed's Board of Directors and look forward to working with the leadership team
to enhance the development of therapeutic applications of the company's oral
drug delivery technology and in the further maturation of
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented flagship product,
an orally ingestible insulin capsule currently in Phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years of research
performed by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
information, please visit http://www.oramed.com
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
and Investor Relation Contacts: